Literature DB >> 9005871

Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations.

M C Dalakas1, I Illa, E Gallardo, C Juarez.   

Abstract

Serum from 70 patients with sporadic inclusion body myositis (IBM) was subjected to agarose gel immunofixation electrophoresis. The IgG extracted from 9 patients with monoclonal proteins, 3 without, and 2 control subjects and was purified, biotinylated, and applied to muscle biopsy sections for immunocytochemistry and to purified muscle protein fractions for immunoblots. Sixteen of 70 (22.8%) patients with IBM, compared with 2% of age-matched controls, had a monoclonal gammopathy characterized as IgG lambda in 9 patients, IgG kappa in 4, IgM kappa in 2, and IgA lambda in 1. The mean age of IBM patients with gammopathy was 60.6 years (range, 35-77 years), compared with 66.1 years (range, 42-80 years) of the IBM patients without gammopathy. The IgG of the patients, more often than that of the control subjects, immunostained myonuclei and recognized various muscle proteins of 35 to 145 kd. We conclude that IBM, regardless of age, is frequently associated with monoclonal gammopathies, which often recognize various muscle components, especially myonuclei, suggesting disturbed immunoregulation.

Entities:  

Mesh:

Year:  1997        PMID: 9005871     DOI: 10.1002/ana.410410116

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis.

Authors:  Jason Hom; Shruti Marwaha; Anna Postolova; Jessie Kittle; Rosaline Vasquez; Jean Davidson; Jennefer Kohler; Annika Dries; Liliana Fernandez-Betancourt; Marta Majcherska; Joanna Dearlove; Shyam Raghavan; Hannes Vogel; Jonathan A Bernstein; Paul Fisher; Euan Ashley; Jacinda Sampson; Matthew Wheeler
Journal:  J Gen Intern Med       Date:  2019-03-18       Impact factor: 5.128

Review 2.  Targeted immunotherapy trials for idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

3.  Autoantibodies against a 43 KDa muscle protein in inclusion body myositis.

Authors:  Mohammad Salajegheh; Theresa Lam; Steven A Greenberg
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

Review 4.  Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies.

Authors:  Cecilia Grundtman; Vivianne Malmström; Ingrid E Lundberg
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

5.  Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology.

Authors:  Ali Alshehri; Rati Choksi; Robert Bucelli; Alan Pestronk
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-06-04

Review 6.  Immune and myodegenerative pathomechanisms in inclusion body myositis.

Authors:  Christian W Keller; Jens Schmidt; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2017-05-16       Impact factor: 4.511

Review 7.  Inclusion Body Myositis and Neoplasia: A Narrative Review.

Authors:  Laura Damian; Cristian Cezar Login; Carolina Solomon; Cristina Belizna; Svetlana Encica; Laura Urian; Ciprian Jurcut; Bogdan Stancu; Romana Vulturar
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

8.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20

9.  Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis.

Authors:  Arundhati Ray; Anthony A Amato; Elizabeth M Bradshaw; Kevin J Felice; Daniel B DiCapua; Jonathan M Goldstein; Ingrid E Lundberg; Richard J Nowak; Hidde L Ploegh; Eric Spooner; Qian Wu; Simon N Willis; Kevin C O'Connor
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.